Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-24
2007-07-24
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S147000
Reexamination Certificate
active
10511452
ABSTRACT:
Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder. The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of pain or migraine
REFERENCES:
patent: 4902695 (1990-02-01), Ornstein
patent: 5356902 (1994-10-01), Ornstein
patent: 5446051 (1995-08-01), Ornstein
patent: 5670516 (1997-09-01), Arnold et al.
patent: 5675008 (1997-10-01), Bertsch et al.
patent: 5767117 (1998-06-01), Moskovitz
patent: 0 590 789 (1994-04-01), None
patent: WO 8801615 (1988-03-01), None
patent: WO 98/45270 (1998-10-01), None
patent: WO 01/01972 (2001-01-01), None
patent: WO 01/02367 (2001-01-01), None
patent: WO 01/46173 (2001-06-01), None
patent: WO 02/053555 (2002-07-01), None
patent: WO 02/053556 (2002-07-01), None
patent: WO 03/024453 (2003-03-01), None
patent: WO 03/024934 (2003-03-01), None
patent: WO 03/082856 (2003-10-01), None
Schoepp, Meuropharmacology, vol. 34(9), 1159-1168, 1995.
Bundgaard, J of Med Chem, vol. 28 (8), 979-981, 1985.
Wang, Current Medicinal Chemistry, vol. 7, pp. 437-453, 2000.
Wang Current Medicinal Chemistry, vol. 7, pp. 437-453, 2000.
Stinchcomb, Pharmaceutical Research, vol. 13, No. 10, pp. 1519-1523, 1996.
Stinchcomb, J of Pharmaceutical Sciences, vol. 91, No. 12, pp. 2571-2578, 2002.□□.
Doh, J of PHarmaceutical Scences, vol. 92, No. 5, pp. 1008-1017, 2003.
Kao, Pharmaceutical Research, vol. 17, No. 8, pp. 978-984, 2000.
Bibby, International Journal of Pharmaceutics, vol. 144, pp. 61-70, 1996.
Bleakman, et al., “Pharmacological Discrimination of GLUR5 and GLUR6 Kainate Receptor Subtypes by (3S,4AR,6R,8AR)-6-2-(1(2)H-Tetrazole-5-yl)Ethyl Decahydroisoquinoline-3 Carboxylic Acid,” Molecular Pharmacology, Baltimore, MD, vol. 49, No. 4, pp. 581-585; XP000942899 (1996).
Buchwald, P. and Bodor, N., Quantitative Structure-Metabolism Relationships: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of noncongener Carboxylic Esters, J. Med. Chem. 42, 5160-5168, 1999.
Tanino, T., Ogiso, t., Iwaki, M., Tanabe, G. and Muraoka, O., Enhancement of Oral Bioavailability of Phenytoin by Esterification, and in vitro Hydrolytic Characteristics of Prodrugs, International Journal of Pharmaceutics 163, 91-102, 1998.
Shindo, H. Fukuda, K., Kawai, K. and Tanaka, K., Studies on Intestinal Absorption of Pivampicillin and Species Difference in the Intestinal Esterase Activity, J. Pharm. Dyn. 1, 310-323, 1978.
O'Neill, MJ, et al., “Decahydroisoquinolines: Novel competitive AMPA/kainite antagonists with neuroprotective effects in global cerebral ischaemia,”Neuropharmacology, 37, pp. 1211-1222 (1998).
Sahara, Y, et al., “Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons,”The Journal of Neuroscience, 17(17), pp. 6611-6620 (1997).
Alam, Z., et al., “Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache,”Journal of Neurological Sciences, 156, pp. 102-106 (1998).
Ornstein, et al., Structure-Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity, J. Med. Chem., vol. 39, No. 11, pp. 2232-2244 (1996).
Procter, et al., “Possible role of GluR5 glutamate receptors in spinal nociceptive processing in the anaesthetized rat,” Journal of Physiology, XX, XX, vol. 405P, pp. 101P-102P; XP002108296 (1997).
Nakam, et al., “The search for AMPA/Gly(N) receptor antagonists,” Drugs Future, vol. 24, No. 10, pp. 1107-1124; XP000997758 (1999).
Procter, et al., “Actions of kainite and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord,” Neuropharmacology, Oct.-Nov. 1998, 37 (10-11), pp. 1287-1297; XP000997628 .
Bleakman, “Kainate receptor pharmacology and physiology,” Cellular and Molecular Life Sciences, 56/7-8 (558-566); XP000990931.
Simmons, et al., “Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat,” Neuropharmacology, 37(1), pp. 25-36; XP000997629 (1998).
Database Medline “Online”, US National Library of Medicine (NLM), Bethesda, MD, US; Mitsikostas D.D., et al, “Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis,” retrieved from DIALOG, Database accession No. 10003939; XP002165715 abstracct & British Journal of Pharmacology, Jun. 1999 (127 (3); pp. 623-630.
Slides that accompanied an oral presentation of the named inventor, Paul Leslie Ornstein, at Medicinal Chemistry Gordon Research Conference, Aug. 9, 2001, Colby Sawyer College, New Hampshire.
James Eckstein, Poster presentation “Disposition of the Novel AMPA Antagonist, LY293558, in Rats and Dogs Following Intravenous Administration” given at the American Association of Pharmaceutical Sciences meeting, San Diego, California, Jun. 1994.
Eli Lilly and Company
Seaman D. Margaret
Wilson Alexander
LandOfFree
Ester derivatives of a decahydroisoquinoline-3-carboxylic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ester derivatives of a decahydroisoquinoline-3-carboxylic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ester derivatives of a decahydroisoquinoline-3-carboxylic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787989